Other Stories

Court suspends watchdog's disciplinary action against Samsung BioLogics Updated: 2019-01-22 15:48:09 KST

The Seoul Administrative Court has suspended the financial watchdog's disciplinary actions against Samsung BioLogics.
Last November, the biopharmaceutical arm of Samsung Group filed an administrative lawsuit against the country's financial regulator over its ruling on the firm's accounting violations.
Earlier in the same month, the Financial Services Commission ruled that Samsung BioLogics intentionally changed its accounting method to inflate the value of its affiliate called Samsung Bioepis in 2015.
The regulator ordered a fine of around seven-million U.S. dollars and recommended firing the firm's CEO.
KOGL : Korea Open Government License
본 저작물 중 본문에 해당하는 뉴스 스크립트(텍스트)는 공공누리 제1유형-출처표시 조건에 따라 이용할 수 있습니다.
weather